Project Grant K08HL175223
Award Date 9/19/25
Completion Date 8/31/30
Dollars Obligated $171K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $491,056.01 to fund research on the role of the vascular smooth muscle protein VPS34 in the development and progression of pulmonary arterial hypertension (PAH). The principal investigator hypothesizes that VPS34 activation in a manner dependent on the AKT signaling pathway promotes the hyperproliferation of pulmonary artery vascular smooth muscle cells, leading...
- This Project Grant award, valued at $1,385,536.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Rhode Island Hospital, a division of Lifespan Corporation. The award, with a period of performance from March 1, 2025 to December 31, 2028, will support research focused on understanding endothelial cell dysfunction and the role of anoikis resistance in the development and progression of pulmonary arterial...
- This federal Project Grant award of $618,450.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on identifying key regulators of vascular homeostasis and understanding how they maintain normal vascular function. The principal investigator will use a combination of in silico and in vitro screening approaches to identify the RNA-binding protein PABPC1 as a critical suppressor of endothelial cell activation, which can...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $143,819 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of New Mexico Health Sciences Center (UNM HSC) on February 3, 2025. The purpose of this grant is to study the role of mitochondrial acid-sensing ion channel 1 (ASIC1) in pulmonary hypertension, a condition characterized by increased constriction and remodeling of the pulmonary arteries. The research aims to define the mechanisms...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $226,101 to the University of Rochester to conduct research on pulmonary angioblasts, which are vital for vascular regeneration and treating vascular diseases. The project aims to leverage existing single-cell RNA sequencing data to explore the cellular characteristics and regulatory mechanisms governing angioblasts, their derived cells, and the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $193,896 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The 3-year grant, with a start date of March 1, 2025, aims to identify clinically available metrics that can serve as surrogates for right ventricular-pulmonary artery (RV-PA) coupling, a key indicator of right ventricular adaptation in pulmonary arterial hypertension (PAH) patients. The research will evaluate the...
- This federal Project Grant award of $522,794 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The research aims to apply transgenic mice and complementary in vivo approaches to delineate HV1's contributions to the pathogenesis of pulmonary hypertension, examine the molecular mechanisms of HV1-mediated pulmonary...
- This $811,370 federal Project Grant was awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Vanderbilt University Medical Center on September 1, 2025 for a 5-year period ending on August 31, 2030. The grant supports scientific research to understand the role of the Hippo-YAP/TAZ signaling pathway in regulating alveolar epithelial cell regeneration during lung repair, with the goal of uncovering mechanisms underlying pulmonary fibrosis, a...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $514,484 Project Grant to The Johns Hopkins University under the Cardiovascular Diseases Research program (CFDA 93.837) on August 24, 2025. The grant supports research to investigate the role of the kynurenine pathway, a metabolic process, in the pathobiology of pulmonary arterial hypertension (PAH). The key objectives are to determine if the enzyme tryptophan 2,3 dioxygenase (TDO) and its metabolite kynurenine serve as endogenous...
- The federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,624 to Vanderbilt University Medical Center to study the role of hypoxia-inducible factor (HIF) in alveolar regeneration and the treatment of idiopathic pulmonary fibrosis (IPF). The research aims to investigate upstream disease mechanisms that could lead to new therapies to promote functional alveolar repair for IPF and other chronic lung diseases....